Perry A. Bernocchi
Known title: EVP, CEO,. Patient DirectCIK: 0001967402
Associated companies
Transaction History
| ACH | ▼ Sell | Tax Withholding | 7,908 | $24K | 5/15/2026 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 20,841 | $42K | 3/20/2026 | View on chart |
| ACH | ▲ Buy | Grant | 108,696 | $0 | 3/9/2026 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 13,394 | $94K | 5/15/2025 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 5,551 | $56K | 3/20/2025 | View on chart |
| ACH | ▲ Buy | Grant | 123,391 | $0 | 3/3/2025 | View on chart |
| ACH | ▼ Sell | Open Market | 1,884 | $33K | 6/6/2024 | View on chart |
| ACH | ▼ Sell | Open Market | 2,833 | $50K | 6/6/2024 | View on chart |
| ACH | ▼ Sell | Open Market | 10,756 | $188K | 6/6/2024 | View on chart |
| ACH | ▼ Sell | Open Market | 4,542 | $79K | 6/6/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 20,962 | $415K | 5/15/2024 | View on chart |
| ACH | ▼ Sell | Open Market | 3,890 | $95K | 5/1/2024 | View on chart |
| ACH | ▼ Sell | Open Market | 20,204 | $490K | 5/1/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 14,946 | $374K | 3/15/2024 | View on chart |
| ACH | ▲ Buy | Grant | 44,643 | $0 | 3/1/2024 | View on chart |
| ACH | ▲ Buy | Grant | 547 | $9K | 12/29/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 19,302 | $362K | 11/22/2023 | View on chart |
| ACH | ▲ Buy | Grant | 554 | $9K | 6/30/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 6,998 | $131K | 5/15/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 6,583 | $121K | 5/11/2023 | View on chart |
| ACH | ▲ Buy | Grant | 64,767 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 35,150 | $0 | 3/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.